{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:49:45Z","timestamp":1762422585729,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.anpede.2020.12.019","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:30:48Z","timestamp":1644280248000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital"],"prefix":"10.1016","volume":"96","author":[{"given":"Beatriz","family":"Guzm\u00e1n Morais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flor \u00c1ngel","family":"Ord\u00f3\u00f1ez \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Santos Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mart\u00edn Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Fern\u00e1ndez Novo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpede.2020.12.019_bib0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.anpede.2020.12.019_bib0010","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00467-015-3120-8","article-title":"Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotics syndrome","volume":"30","author":"Counsilman","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0015","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.anpede.2020.12.019_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0025","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","article-title":"Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome","volume":"26","author":"Ito","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0030","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1542\/peds.2015-0486","article-title":"Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome","volume":"136","author":"Basu","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.anpede.2020.12.019_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","article-title":"Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study","volume":"34","author":"Takahashi","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0040","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","article-title":"Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases","volume":"23","author":"Guigonis","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0045","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2215\/CJN.03470410","article-title":"Efficacy and safety of treatment with rituximab for difficult steroid-resistant and \u2014 dependent nephrotic syndrome: multicentric report","volume":"5","author":"Gulati","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0050","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","article-title":"Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children","volume":"24","author":"Kamei","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0055","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.anpede.2020.12.019_bib0060","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","article-title":"Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome","volume":"31","author":"Webb","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0065","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.anpede.2020.12.019_bib0070","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1056\/NEJMc063706","article-title":"Rituximab in patients with the steroid-resistant nephrotic syndrome","volume":"356","author":"Bagga","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anpede.2020.12.019_bib0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/1440-1681.13046","article-title":"Multicenter analysis of the efficacy and safety of a non-standard immunosuppressive therapy with rituximab in children with steroid-resistant nephrotic syndrome","volume":"46","author":"Zachwieja","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.anpede.2020.12.019_bib0085","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.anpede.2020.12.019_bib0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00467-018-4145-6","article-title":"Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome","volume":"34","author":"Fujinaga","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0095","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12882-019-1470-3","article-title":"Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial)","volume":"20","author":"Nagano","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","article-title":"Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome","volume":"84","author":"Bhatia","year":"2018","journal-title":"Pediatr Res"},{"key":"10.1016\/j.anpede.2020.12.019_bib0110","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","article-title":"Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion","volume":"22","author":"Sato","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ckj\/sfy067","article-title":"Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome","volume":"12","author":"Cortazar","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.anpede.2020.12.019_bib0120","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","article-title":"Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2014follow-up after CD19 recovery","volume":"27","author":"Sellier-Leclerc","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.anpede.2020.12.019_bib0125","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1681\/ASN.2006121346","article-title":"A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.anpede.2020.12.019_bib0130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ki.1991.232","article-title":"A glomerular permeability factor produced by human T cell hybridomas","volume":"40","author":"Koyama","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.anpede.2020.12.019_bib0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","article-title":"NEPHRUTIX: a randomized, double-blind, placebo vs Rituximab- controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome","volume":"88","author":"Boumediene","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.anpede.2020.12.019_bib0140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.anpede.2020.12.019_bib0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fped.2019.00313","article-title":"Rituximab for children with difficult-to-treat nephrotic syndrome: its effects on disease progression and growth","volume":"7","author":"Topalo\u011flu","year":"2019","journal-title":"Front Pediatr"}],"container-title":["Anales de Pediatr\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2341287922000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2341287922000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:44:35Z","timestamp":1762422275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2341287922000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2341287922000035"],"URL":"https:\/\/doi.org\/10.1016\/j.anpede.2020.12.019","relation":{},"ISSN":["2341-2879"],"issn-type":[{"type":"print","value":"2341-2879"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpede.2020.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2020.12.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda.","name":"copyright","label":"Copyright"}]}}